Vandetanib
- Generic Name
- Vandetanib
- Brand Names
- Caprelsa
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24BrFN4O2
- CAS Number
- 443913-73-3
- Unique Ingredient Identifier
- YO460OQ37K
- Background
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
- Indication
Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.
- Associated Conditions
- Metastatic Thyroid Gland Medullary Carcinoma, Locally advanced Medullary thyroid cancer
- Associated Therapies
- -
Vandetanib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Diffuse Brainstem Glioma
- First Posted Date
- 2007-05-10
- Last Posted Date
- 2012-10-15
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT00472017
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Phase II, Double Blind Study of 2 Doses of ZACTIMAâ„¢(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 106
- Registration Number
- NCT00454116
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
🇬🇧Research site, Belfast, Northern Ireland, United Kingdom
Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-03-09
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00445549
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 698
- Registration Number
- NCT00418886
- Locations
- 🇻🇪
Research Site, Valencia, Venezuela
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 1574
- Registration Number
- NCT00364351
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-04-10
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 1690
- Registration Number
- NCT00312377
- Locations
- 🇻🇳
Research Site, Ho Chi Minh city, Vietnam
ZD6474 in Treating Patients With Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Genzyme, a Sanofi Company
- Registration Number
- NCT00066313
- Locations
- 🇨🇦
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦Saint John Regional Hospital, Saint John, New Brunswick, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.